PMID- 38537636
OWN - NLM
STAT- MEDLINE
DCOM- 20240419
LR  - 20240502
IS  - 2666-3791 (Electronic)
IS  - 2666-3791 (Linking)
VI  - 5
IP  - 4
DP  - 2024 Apr 16
TI  - Effects of levothyroxine in subclinical hypothyroidism and heart failure with 
      reduced ejection fraction: An open-label randomized trial.
PG  - 101473
LID - S2666-3791(24)00119-8 [pii]
LID - 10.1016/j.xcrm.2024.101473 [doi]
LID - 101473
AB  - We report a randomized, multicenter, open-label trial (ClinicalTrials.gov: 
      NCT03096613) to investigate the clinical benefits of levothyroxine (L-T4) 
      administration in subclinical hypothyroidism (SCH) patients with heart failure 
      with reduced ejection fraction (HFrEF). Overall, 117 patients were enrolled and 
      received L-T4 plus standard HFrEF treatment (experimental group, N = 57) or 
      standard HFrEF therapy alone (control group, N = 60). The change of 6-min walk 
      test distance in the experimental group was significantly higher than that in the 
      control group at 24 weeks (70.08 +/- 85.76 m vs. 27.73 +/- 82.00 m, mean difference 
      [95% confidence interval (CI)] 46.90 [12.90, 80.90], p < 0.001). Improvements in 
      New York Heart Association (NYHA) classification (p = 0.033) and thyroid function 
      were significant. Adverse event incidence was similar between groups (risk ratio 
      [95% CI]: 0.942 1.053 (0.424, 2.616); p = 0.628). L-T4 addition to HFrEF 
      treatment improved activity tolerance, NYHA class, and thyroid function within 
      6 months, suggesting its potential for combined therapy in HFrEF patients with 
      SCH. Future double-blind, placebo-controlled trials should be performed to 
      confirm these results.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Wang, Wenyao
AU  - Wang W
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Key Laboratory of Molecular Cardiovascular Science, Ministry of 
      Education, Beijing, China.
FAU - Zhang, Xuan
AU  - Zhang X
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Gao, Jun
AU  - Gao J
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Key Laboratory of Molecular Cardiovascular Science, Ministry of 
      Education, Beijing, China.
FAU - Meng, Xiangbin
AU  - Meng X
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Key Laboratory of Molecular Cardiovascular Science, Ministry of 
      Education, Beijing, China.
FAU - Wang, Jingjia
AU  - Wang J
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Key Laboratory of Molecular Cardiovascular Science, Ministry of 
      Education, Beijing, China.
FAU - Zhang, Kuo
AU  - Zhang K
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Chen, Jing
AU  - Chen J
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Qi, Jiating
AU  - Qi J
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Key Laboratory of Molecular Cardiovascular Science, Ministry of 
      Education, Beijing, China.
FAU - Shao, Chunli
AU  - Shao C
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Key Laboratory of Molecular Cardiovascular Science, Ministry of 
      Education, Beijing, China.
FAU - Tang, Yi-Da
AU  - Tang YD
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Key Laboratory of Molecular Cardiovascular Science, Ministry of 
      Education, Beijing, China. Electronic address: tangyida@bjmu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT03096613
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20240326
PL  - United States
TA  - Cell Rep Med
JT  - Cell reports. Medicine
JID - 101766894
RN  - Q51BO43MG4 (Thyroxine)
SB  - IM
MH  - Humans
MH  - Double-Blind Method
MH  - *Heart Failure
MH  - *Hypothyroidism/drug therapy
MH  - Stroke Volume
MH  - Thyroxine/therapeutic use
PMC - PMC11031377
OTO - NOTNLM
OT  - 6MWT
OT  - NYHA
OT  - chronic heart failure
OT  - levothyroxine
OT  - subclinical hypothyroidism
COIS- Declaration of interests The authors declare no competing interests.
EDAT- 2024/03/28 00:45
MHDA- 2024/04/19 06:43
PMCR- 2024/03/26
CRDT- 2024/03/27 19:41
PHST- 2023/09/06 00:00 [received]
PHST- 2024/01/05 00:00 [revised]
PHST- 2024/02/21 00:00 [accepted]
PHST- 2024/04/19 06:43 [medline]
PHST- 2024/03/28 00:45 [pubmed]
PHST- 2024/03/27 19:41 [entrez]
PHST- 2024/03/26 00:00 [pmc-release]
AID - S2666-3791(24)00119-8 [pii]
AID - 101473 [pii]
AID - 10.1016/j.xcrm.2024.101473 [doi]
PST - ppublish
SO  - Cell Rep Med. 2024 Apr 16;5(4):101473. doi: 10.1016/j.xcrm.2024.101473. Epub 2024 
      Mar 26.